
CAS 2484719-14-2
:Pyridine, 3-(3-ethoxyandrosta-5,16-dien-17-yl)-
- Pyridine, 3-(3-ethoxyandrosta-5,16-dien-17-yl)-
- Abiraterone impurities427
- Abiraterone Ethyl Ether
- Abiraterone Ethyl Ether Q: What is the CAS Number of
- Abiraterone Impurity 09
- Abiraterone Ethyl EtherQ: What is
Abiraterone Ethyl Ether (3-((3S,8R,9S,10R,13S,14S)-3-ethoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine)
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFormula:C26H35NOColor and Shape:Off-White SolidMolecular weight:377.27186Abiraterone Ethyl Ether
CAS:Controlled ProductApplications Abiraterone Ethyl Ether is an impurity of Abiraterone (A108490), a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
References Denis, L., et al.: Cancer, 72, 3888 (1993); Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995); Denmeade, S., et al.: Nat. Rev., 2, 389(2002); Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005)Formula:C26H35NOColor and Shape:NeatMolecular weight:377.56Abiraterone Ethyl Ether-d5
CAS:Controlled ProductApplications Abiraterone Ethyl Ether-d5 is the labeled analogue of Abiraterone Ethyl Ether (A108525), an impurity of Abiraterone (A108490), a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer.
References Denis, L., et al.: Cancer, 72, 3888 (1993); Potter, G.A., et al.: J. Med. Chem., 38, 2463 (1995); Denmeade, S., et al.: Nat. Rev., 2, 389(2002); Scher, H., et al.: J. Clin. Oncol., 23, 8253 (2005)Formula:C26H30D5NOColor and Shape:NeatMolecular weight:382.59




